Nuvig secures $161m financing to support clinical studies for NVG-2089
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept…
Immunology
-
-
Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
-
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
Sepsis deaths are still high, with 50% mortality within two years
Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its…
-
Priovant mulls broad autoimmune indications for brepocitinib
Priovant Therapeutics has high expectations for its lead candidate brepocitinib and plans to evaluate the therapy in multiple autoimmune indications.…
-
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead has presented updated data for its twice-yearly pre-exposure prophylaxis (PrEP) lenacapavir, which has shown nearly perfect efficacy in two…
-
Resolution scores $83m to develop macrophage cell therapies
Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based…
-
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy
US-based biopharmaceutical company Adicet Bio has begun enrolling patients in a Phase I clinical trial of ADI-001 to treat autoimmune…
-
Union plans Phase III trial for atopic dermatitis after Phase IIb win
Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic dermatitis (AD)…
